All of us contact lens wearers know that it is a good idea to take good care of your lenses or your eyes will suffer. This includes cleaning contact lenses and not wearing your contact lenses for more than eight to ten hours. Here are some tips from the FDA.
The FDA and CDC are urgently advising consumers to take precautions to prevent contamination of the lenses and the products used to maintain them. These preventive practices include:
* Wash hands with soap and water, and dry (lint-free method) before handling lenses.
* Wear and replace lenses according to the schedule prescribed by the doctor.
* Follow the specific lens cleaning and storage guidelines from the doctor and the solution manufacturer.
* Keep the contact lens case clean and replace every 3-6 months.
* Remove the lenses and consult your doctor immediately if you experience symptoms such as redness, pain, tearing, increased light sensitivity, blurry vision, discharge or swelling.
In addition, regardless of which cleaning/disinfecting solution used, wearers may want to consider performing a “rub and rinse” lens cleaning method, rather than a no-rub method, in order to minimize the number of germs and reduce the chances of infection.
Bausch Lomb has recommended that consumers stop using ReNu with MoistureLoc immediately and discard all remaining MoistureLoc solution including partially used or opened bottles. Both the Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC) continue to investigate reports of fungal keratitis in an effort to determine all contributing factors and/or products that may place contact lens wearers at increased risk for Fusarium keratitis. As part of this ongoing investigation, we are continuing joint inspections of the Bausch Lomb plant and facilities in Greenville, SC including testing of products, environmental factors and raw materials. Because of the nature of the organism (Fusarium), extensive microbiological testing is being conducted and may take up to one month to fully analyze. We are committed to continuing a comprehensive approach aimed at determining the cause of these infections and will provide regular updates on our activities through preliminary public health notices issued through FDA.